Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification.

Tytuł:
Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification.
Autorzy:
Lee CL; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.; Tzu Chi University, Hualien, Taiwan.
Jhang JF; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.; Tzu Chi University, Hualien, Taiwan.
Ho HC; Department of Anatomy, Tzu Chi University, Hualien, Taiwan.
Jiang YH; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.; Tzu Chi University, Hualien, Taiwan.
Hsu YH; Department of Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.; Tzu Chi University, Hualien, Taiwan.
Kuo HC; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan. .; Tzu Chi University, Hualien, Taiwan. .
Źródło:
Scientific reports [Sci Rep] 2022 Jan 10; Vol. 12 (1), pp. 362. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Conservative Treatment*/adverse effects
Diagnostic Techniques, Urological*
Urodynamics*
Urologic Surgical Procedures, Male*/adverse effects
Video Recording*
Urethra/*innervation
Urinary Bladder/*innervation
Urinary Bladder, Underactive/*therapy
Urological Agents/*therapeutic use
Acetylcholine Release Inhibitors/therapeutic use ; Aged ; Aged, 80 and over ; Botulinum Toxins, Type A/therapeutic use ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Recovery of Function ; Retrospective Studies ; Time Factors ; Urinary Bladder, Underactive/diagnostic imaging ; Urinary Bladder, Underactive/physiopathology ; Urological Agents/adverse effects
References:
N Engl J Med. 1989 Jan 5;320(1):1-7. (PMID: 2909873)
Neurourol Urodyn. 2020 Nov;39(8):2179-2185. (PMID: 32720738)
Low Urin Tract Symptoms. 2019 Jan;11(1):66-71. (PMID: 29024564)
J Urol. 2003 Apr;169(4):1374-8. (PMID: 12629365)
Neurourol Urodyn. 2018 Nov;37(8):2651-2657. (PMID: 29797345)
Urology. 2007 Jan;69(1):57-61; discussion 61-2. (PMID: 17270614)
Eur Urol. 2015 Sep;68(3):351-3. (PMID: 25770481)
J Urol. 2017 Jan;197(1):197-203. (PMID: 27436428)
J Formos Med Assoc. 2018 Mar;117(3):178-184. (PMID: 28969876)
PLoS One. 2017 Apr 4;12(4):e0174593. (PMID: 28376105)
Int Neurourol J. 2015 Sep;19(3):185-9. (PMID: 26620901)
Int Braz J Urol. 2017 May-Jun;43(3):540-548. (PMID: 28266820)
Urology. 2019 Jan;123:235-241. (PMID: 30308261)
Neurourol Urodyn. 2021 Jan;40(1):228-236. (PMID: 33053242)
Rev Urol. 2013;15(1):11-22. (PMID: 23671401)
J Urol. 2010 Apr;183(4):1288-95. (PMID: 20171668)
J Urol. 1996 Nov;156(5):1748-50. (PMID: 8863586)
Neurourol Urodyn. 2021 Mar;40(3):883-890. (PMID: 33645850)
Urol Int. 1997;59(4):226-30. (PMID: 9444739)
PLoS One. 2018 Jun 20;13(6):e0198764. (PMID: 29924821)
Neurourol Urodyn. 2015 Nov;34(8):752-6. (PMID: 25220925)
Neurourol Urodyn. 2021 Mar;40(3):868-875. (PMID: 33645847)
Int Urogynecol J. 2014 May;25(5):671-6. (PMID: 24288115)
Ci Ji Yi Xue Za Zhi. 2017 Oct-Dec;29(4):187-191. (PMID: 29296045)
J Urol. 2010 Nov;184(5):1829-30. (PMID: 20846686)
Curr Urol Rep. 2009 Sep;10(5):347-51. (PMID: 19709481)
Neurourol Urodyn. 2002;21(2):167-78. (PMID: 11857671)
Urology. 2003 Mar;61(3):550-4. (PMID: 12639645)
J Urol. 2000 Nov;164(5):1640-3. (PMID: 11025724)
Neurourol Urodyn. 2010 Mar;29(3):408-12. (PMID: 19760756)
Low Urin Tract Symptoms. 2020 Jan;12(1):41-46. (PMID: 31430060)
J Neurol Neurosurg Psychiatry. 1997 May;62(5):507-11. (PMID: 9153611)
Substance Nomenclature:
0 (Acetylcholine Release Inhibitors)
0 (Urological Agents)
EC 3.4.24.69 (Botulinum Toxins, Type A)
EC 3.4.24.69 (incobotulinumtoxinA)
Entry Date(s):
Date Created: 20220111 Date Completed: 20220222 Latest Revision: 20220222
Update Code:
20240104
PubMed Central ID:
PMC8748740
DOI:
10.1038/s41598-021-04237-0
PMID:
35013465
Czasopismo naukowe
Detrusor underactivity (DU) could be resulted from many different etiologies. Patients with DU might have reduced bladder sensation, low detrusor contractility, and large post-void residual volume. This study analyzed therapeutic outcome of active management for male DU patients, based on clinical and urodynamic characteristics. Male DU patients aged > 18 years old were retrospectively reviewed from the videourodynamic study (VUDS) records in recent 10 years. The patients' demographics, VUDS results, treatment modalities, and treatment outcome were analyzed. The treatment outcomes were compared among patients with different DU subgroups, clinical diagnosis and treatment modalities. Patients with voiding efficiency of > 66.7% were considered having a successful treatment outcome. For comparison, 30 men with normal VUDS finding served as the control arm. Most of the DU patients had reduced bladder sensation. The reduced bladder sensation is closely associated with low detrusor contractility. After active treatment, a successful outcome was achieved in 68.4% of patients after bladder outlet surgery, 59.1% after urethral botulinum toxin A injection, and 57.6% after medical treatment, but only 18.2% after conservative treatment. A successful treatment outcome was achieved in patients with an intact detrusor contractility, either low (69.2%) or normal voiding pressure (81.8%), and in patients with a normal or increased bladder sensation (78.1%). However, patients with detrusor acontractile (41.3%) or absent bladder sensation (17.9%) had less favorable treatment outcome after any kind of urological management. This study revealed that active management can effectively improve voiding efficiency in patients with DU. The normal bladder sensation, presence of adequate detrusor contractility, and bladder outlet narrowing during VUDS provide effective treatment strategy for DU patients. Among all management, BOO surgery provides the best treatment outcome.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies